Added 10 days ago Drug news
Phase III PERSIST-2 trial of SB 1518 in myelofibrosis published in JAMA Oncology.- CTI BioPharma Corp.
CTI BioPharma Corp announced that results from the Phase III PERSIST-2 clinical trial of SB 1518 (pacritinib) have been published...
Added 5 months ago Drug news
Impact Biomedicines announced its launch to pioneer the development of life-changing treatments for patients with myeloproliferative neoplasms and other cancers. The...
Added 1 year ago Drug news
FDA's clinical hold on all trials of SB 1518 (pacritinib) for patients with myelofibrosis now removed- CTI BioPharma
CTI BioPharma announced that the full clinical hold (February 2016) implemented by the FDA on all clinical trials conducted under...
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Discover and overview of hypophosphatasia and details required to facilitate the timely and accurate detection of low alkaline phosphatase.
What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.
Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.
See information on best practice in solid organ transplantation, and expert discussions on related hot topics.
Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012
Guidelines for myelofibrosis were produced in 2012 (Reilly et al, 2012), but since then Ruxolitinib, a JAK1/JAK2 inhibitor, has been approved for use in the European Union and highly prevalent mutations in the Calreticulin gene (CALR)...
Added 3 years ago
Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Philadelphia chromosome negative chronic myeloproliferative neoplasms include polycythaemia vera, essential thrombocythaemia and primary myelofibrosis. The new ESMO Clinical Practice Guidelines...
Added 2 years ago
The purpose of this guideline is to provide a practical, rather than a research, approach to the diagnosis, investigation and management of patients with primary myelofibrosis, as well as post-polycythaemic myelofibrosis (post-PV MF) and...
Added 5 years ago
Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network.
Ascertainment of cases and disease classification is an acknowledged problem for epidemiological research into haematological malignancies.
Added 6 months ago
A rapid increase in awareness of androgen deficiency has led to substantial increases in prescribing of testosterone therapy (TTh), with benefits of improvements in mood, libido, bone density, muscle mass, body composition, energy, and cognition.
Added 8 months ago
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm classified according to the 2016 revision of World Health Organization Classification of Tumors and Haematopoietic and Lymphoid Tissue.
Added 9 months ago